Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.
Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.
复制标题
回顾性全国范围内关于日本2型糖尿病患者一线抗糖尿病药物的趋势的研究。
DOI：
10.1111/jdi.13636
复制
发表时间：
2022-03
影响因子：
3.2
通讯作者：
Ueki K
中科院分区：
文献类型：
--
作者：
Bouchi R;Sugiyama T;Goto A;Imai K;Ihana-Sugiyama N;Ohsugi M;Yamauchi T;Kadowaki T;Ueki K
研究日本2型糖尿病患者一线非胰岛素降糖药处方和处方药物后的总医疗费用（TMC）的全国趋势。我们使用几乎涵盖日本全体人口的日本国家健康保险索赔和特定健康检查数据库，计算了2014年至2017年每种降糖药物的比例，并确定了与药物选择相关的因素。计算开始用药后第一年的TMC，并确定与成本相关的因素。在1，136，723名新使用降糖药的患者中，二肽基肽酶-4抑制剂的处方最多（65.1%），其次是双胍类（15.9%）和钠-葡萄糖协同转运蛋白2抑制剂（7.6%）。钠-葡萄糖协同转运蛋白2抑制剂和双胍类药物的使用在2014-2017年期间增加（分别为2.2%-11.4%和13.7%-17.2%），而其他药物则下降。在38.2%的非日本糖尿病协会认证的机构中，根本没有开双胍类药物。以双胍类药物为起始药物的受试者中TMC最低。财政年度、年龄、性别、设施、床位数和合并症与药物选择和TMC相关。在药物选择方面存在广泛的区域差异，但在TMC方面没有差异。与美国和欧洲不同，二肽基肽酶-4抑制剂是日本2型糖尿病患者最常用的一线药物，而不同设施类型和地区的药物选择差异很大。在这项针对日本2型糖尿病患者的大规模全国性研究中，二肽基肽酶-4抑制剂是最常用的处方药，其次是双胍类，不同机构和地区的药物选择差异很大。开始使用双胍类药物的患者的总医疗费用最低。
To investigate the national trend in the prescription of first‐line non‐insulin antidiabetic agents and total medical costs (TMCs) after prescribing the drug in Japanese patients with type 2 diabetes. Using the National Database of Health Insurance Claims and Specific Health Check‐ups of Japan covering almost the entire Japanese population, we calculated the proportion of each antidiabetic drug from 2014 to 2017, and determined the factors associated with drug selection. The TMCs in the first year after starting the drugs were calculated, and factors associated with the costs were also determined. Among 1,136,723 new users of antidiabetic agents, dipeptidyl peptidase‐4 inhibitors were the most prescribed (65.1%), followed by biguanides (15.9%) and sodium–glucose cotransporter 2 inhibitors (7.6%). Sodium–glucose cotransporter 2 inhibitor and biguanide use increased during 2014–2017 (2.2%–11.4% and 13.7%–17.2%, respectively), whereas the others decreased. Biguanides were not prescribed at all in 38.2% of non‐Japan Diabetes Society‐certified facilities. The TMCs were the lowest among those who started with biguanides. Fiscal year, age, sex, facility, number of beds and comorbidities were associated with drug choice and TMCs. There were wide regional variations in the drug choice, but not in the TMCs. Unlike in the USA and Europe, dipeptidyl peptidase‐4 inhibitor is the most prescribed first‐line medication for type 2 diabetes patients in Japan, while there is a wide variation in the drug choice by facility‐type and prefecture. In this large‐scale, nationwide study of Japanese patients with type 2 diabetes, dipeptidyl peptidase‐4 inhibitors were the most prescribed followed by biguanides, with a wide variation in the drug choice by facility and prefecture. The total medical costs were the lowest among patients who started with biguanides.
登录
查看更多内容
DOI：
10.1111/dom.13346
发表时间：
2018-09
期刊：
Diabetes, obesity & metabolism
影响因子：
--
作者：
Curtis HJ;Dennis JM;Shields BM;Walker AJ;Bacon S;Hattersley AT;Jones AG;Goldacre B
通讯作者：
Goldacre B
影响因子：
2.2
作者：
Sugiyama, Takehiro;Miyo, Kengo;Kajio, Hiroshi
通讯作者：
Kajio, Hiroshi
影响因子：
3.2
作者：
Weng, Wayne;Liang, Yuanjie;Bouchard, Jonathan
通讯作者：
Bouchard, Jonathan
影响因子：
3.2
作者：
Seino Y;Kuwata H;Yabe D
通讯作者：
Yabe D
DOI：
10.1056/nejmoa1603827
发表时间：
2016-07-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Marso SP;Daniels GH;Brown-Frandsen K;Kristensen P;Mann JF;Nauck MA;Nissen SE;Pocock S;Poulter NR;Ravn LS;Steinberg WM;Stockner M;Zinman B;Bergenstal RM;Buse JB;LEADER Steering Committee;LEADER Trial Investigators
通讯作者：
LEADER Trial Investigators